Cel Sci Corp
CEL SCI CORP develops and commercializes pharmaceutical products, primarily focused on oncology treatments, with a key product candidate Multikine in clinical trials for bladder cancer.
Business. CEL-SCI Corp (NYSE: CVM) is a pharmaceutical company operating within the Healthcare sector. The firm engages in the development and sale of pharmaceutical products. Headquarters and specific operating segment details are not provided in the available data. The company is primarily listed on the New York Stock Exchange under the ticker symbol CVM.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
1Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsFY 2026 earnings (expected)2026-11-09 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Cel-sci Corp (CVM) has recorded a notable new institutional position, with investor ID 466 adding 774,704 shares as of June 30, 2024. This acquisition represents a portfolio weight of approximately 0.00002% and a total value of roughly $0.9 million. This activity marks the first significant holder change detected for the ticker, establishing a baseline for future ownership tracking. The significance of this entry is contextualized by the company's current market profile, which includes eight top holders but zero analyst coverage and no index memberships. With no officers currently listed in the available data, the addition of a new institutional stakeholder may signal early interest from the investment community despite the lack of traditional financial research coverage. Market attention for Cel-sci Corp remains minimal, with cross-source signals showing virtually no dispatch activity over the past month. Only a single dispatch was recorded on July 9, 2026, while the surrounding days showed zero activity, indicating a quiet period in terms of public news flow or sentiment generation. As this is the first analysis for CVM, there is no prior basis for computing material changes or deltas. The current snapshot relies on the newly identified holder activity and the existing company structure, providing a foundational view of the firm's ownership landscape without historical comparison points.
Signals & dispatch
Composite-score breakdown
Synthesis
CEL-SCI Corp (NYSE: CVM) is a pharmaceutical company operating within the Healthcare sector. The firm engages in the development and sale of pharmaceutical products. Headquarters and specific operating segment details are not provided in the available data. The company is primarily listed on the New York Stock Exchange under the ticker symbol CVM.
CEL SCI CORP's capital structure is marked by a high debt-to-equity ratio of 0.83 and a current ratio of 0.6, indicating that current liabilities exceed current assets. The company's liquidity position is further strained by a negative operating cash flow of -$8,044,494 and a free cash flow of the same amount, with no capital expenditures recorded. The price-to-book ratio of 1.91 suggests that the market value is somewhat higher than the book value, but the negative return on equity of -1.59 and return on assets of -0.62 highlight poor profitability.
Profitability metrics for CEL SCI CORP are significantly below industry norms, with a negative net income of -$10,935,197 and an operating income of -$10,694,815. The company's return on equity and return on assets are also negative, indicating that it is not generating returns on its equity or assets. These figures suggest that the company is struggling to convert its investments into profits, which is a concern for investors.
The company's revenue is primarily concentrated in the United States, with no significant geographic diversification reported. The lack of geographic diversification increases the company's exposure to local market conditions and regulatory changes. Additionally, the company's reliance on a single product candidate, Multikine, for its future growth is a significant risk.
The growth trajectory of CEL SCI CORP is uncertain, with a net decrease in cash and cash equivalents of $9,062,728 in the six months ended March 31, 2026. The company's liquidity position is further exacerbated by the substantial doubt about its ability to continue as a going concern, as noted in its filings. The company's future financial performance is contingent on the success of its clinical trials and the potential approval of Multikine.
The risk assessment for CEL SCI CORP indicates a high liquidity risk and a medium dilution risk. The company's filings reference going-concern or substantial-doubt language, and there are mentions of dilution or offering risk. The company's debt-to-equity ratio of 0.83 and the negative operating cash flow contribute to the liquidity risk. The dilution risk is further compounded by the company's need to raise additional capital to fund its operations.
Recent events, as detailed in the company's filings, include a net loss of $10,935,197 and a net cash used in operating activities of $8,044,494. The company has also recognized an impairment loss on its patents, which is a concern for its asset valuation. The company's ability to continue as a going concern is in doubt due to recurring losses and future liquidity needs. The company has expanded its manufacturing facility to meet potential demand for Multikine if approved.
Cel-sci Corp (CVM) has recorded a notable new institutional position, with investor ID 466 adding 774,704 shares as of June 30, 2024. This acquisition represents a portfolio weight of approximately 0.00002% and a total value of roughly $0.9 million. This activity marks the first significant holder change detected for the ticker, establishing a baseline for future ownership tracking. The significance of this entry is contextualized by the company's current market profile, which includes eight top holders but zero analyst coverage and no index memberships. With no officers currently listed in the available data, the addition of a new institutional stakeholder may signal early interest from the investment community despite the lack of traditional financial research coverage. Market attention for Cel-sci Corp remains minimal, with cross-source signals showing virtually no dispatch activity over the past month. Only a single dispatch was recorded on July 9, 2026, while the surrounding days showed zero activity, indicating a quiet period in terms of public news flow or sentiment generation. As this is the first analysis for CVM, there is no prior basis for computing material changes or deltas. The current snapshot relies on the newly identified holder activity and the existing company structure, providing a foundational view of the firm's ownership landscape without historical comparison points.
- CEL SCI CORP is a pharmaceutical company focused on oncology treatments, with a key product candidate Multikine in clinical trials for bladder cancer.
- The company's financial position is weak, with a high debt-to-equity ratio, negative operating and net income, and a current ratio below 1.
- Profitability metrics are significantly below industry norms, with negative returns on equity and assets.
- The company's revenue is concentrated in the United States, and it relies heavily on a single product candidate for future growth.
- The company faces high liquidity risk and medium dilution risk, with substantial doubt about its ability to continue as a going concern.
- Recent events include a net loss, impairment loss on patents, and expansion of the manufacturing facility to meet potential demand for Multikine.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Operating income -$10.7M.
- ▍Operating income -$10.7M
Operating income -$5.4M.
- ▍Operating income -$5.4M
Operating income -$24.8M.
- ▍Operating income -$24.8M
Operating income -$26.4M.
- ▍Operating income -$26.4M
Operating income -$26.4M.
- ▍Operating income -$26.4M
Operating income -$31.5M.
- ▍Operating income -$31.5M
Operating income -$31.5M.
- ▍Operating income -$31.5M
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -4,16 |
| Revenue | —no estimate | —no estimate | 0 USD |
| Operating income | —no estimate | —no estimate | 1,000 USD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Current liabilities exceed current assets.
- Net cash is negative after subtracting total debt.
- Filings reference going-concern or substantial-doubt language.
- Source documents mention dilution or offering risk.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- Director · Options → Common StockAcquired 4 000 @ $8,20grant · 2025-07-28
- Chief Scientific Officer · Options → Common StockAcquired 15 000 @ $8,20grant · 2025-07-28
- Chief Financial Officer · Options → Common StockAcquired 12 000 @ $8,20grant · 2025-07-28
- Director, Chief Executive Officer · Options → Common StockAcquired 25 000 @ $8,20grant · 2025-07-28
- Director · Options → Common StockAcquired 4 000 @ $8,20grant · 2025-07-28
- Senior Vice President · Options → Common StockAcquired 7 500 @ $8,20grant · 2025-07-28
Physical assets
4 tracked| Asset | Type | Commodity | Country | Role |
|---|---|---|---|---|
| MANZANILLO 2 | Vessel | — | North Sea | Registered owner |
| MANZANILLO 2 | Vessel | — | North Sea | Manager |
| TSHUAPA | Vessel | — | — | Registered owner |
| TSHUAPA | Vessel | — | — | Manager |
Actions
Ask Handelsavisen
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- CEL SCI CORP company facts · 2026-05-27
- CEL SCI CORP 10-Q 2026-05-15 · 2026-05-27
- CEL SCI CORP 10-Q 2026-02-17 · 2026-05-27
- CEL SCI CORP 10-K 2025-12-29 · 2026-05-27
- CEL SCI CORP 10-Q 2025-08-14 · 2026-05-27
Ownership & reference
Insider activity
- Director, Chief Executive Officer · Common StockOther 5 192 @ $1,04$5K · 2026-06-30
- Chief Financial Officer · Common StockOther 4 125 @ $1,04$4K · 2026-06-30
- Chief Scientific Officer · Common StockOther 2 307 @ $1,04$2K · 2026-06-30
- Director, Chief Executive Officer · Common StockBought 300 000 @ $1,20$360K · 2026-05-14
- Director, Chief Executive Officer · Common StockBought 100 000 @ $1,19$119K · 2026-05-13
- Director, Chief Executive Officer · Common StockOther 1 682 @ $3,21$5K · 2026-03-31
- Chief Scientific Officer · Common StockOther 747 @ $3,21$2K · 2026-03-31
- Chief Financial Officer · Common StockOther 1 336 @ $3,21$4K · 2026-03-31
- Director, Chief Executive Officer · Common StockBought 38 023 @ $5,26$200K · 2026-01-22
- Chief Financial Officer · Common StockOther 815 @ $5,26$4K · 2025-12-31
- Chief Scientific Officer · Common StockOther 456 @ $5,26$2K · 2025-12-31
- Director, Chief Executive Officer · Common StockOther 998 @ $5,26$5K · 2025-12-31
- Director, Chief Executive Officer · Common StockBought 8 389 @ $5,96$50K · 2025-12-04
- Chief Scientific Officer · Common StockOther 260 @ $9,20$2K · 2025-09-30
- Chief Financial Officer · Common StockOther 466 @ $9,20$4K · 2025-09-30
- Director, Chief Executive Officer · Common StockOther 570 @ $9,20$5K · 2025-09-30
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -1.5%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -18.3%Derived (calculated)
- Current ratio (FY 2025-12-31): 1.39xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 1.06xDerived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): -10.9%Derived (calculated)
- Shareholders' equity (annual): USD 11.14MSEC XBRL filing
- Shares outstanding (annual): 8.42MSEC XBRL filing
- Current assets (annual): USD 7.03MSEC XBRL filing
- Total liabilities (annual): USD 11.76MSEC XBRL filing
- Current liabilities (annual): USD 5.04MSEC XBRL filing
- Total assets (annual): USD 22.89MSEC XBRL filing
- Operating cash flow (YoY) (2025-09-30 vs 2024-09-30): 9.0%Derived (calculated)
- Capex (YoY) (2025-09-30 vs 2024-09-30): -59.8%Derived (calculated)
- R&D expense (YoY) (2025-09-30 vs 2024-09-30): -12.5%Derived (calculated)
- EPS (diluted) (YoY) (2025-09-30 vs 2024-09-30): 59.0%Derived (calculated)
- Operating income (YoY) (2025-09-30 vs 2024-09-30): 5.9%Derived (calculated)
- Net income (YoY) (2025-09-30 vs 2024-09-30): 5.6%Derived (calculated)
- Capex (annual): USD 38.11KSEC XBRL filing
- Net income (annual): USD -25.41MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES -6SEC XBRL filing
- Interest expense (annual): USD 649KSEC XBRL filing
- Operating cash flow (annual): USD -17.12MSEC XBRL filing
- R&D expense (annual): USD 15.89MSEC XBRL filing
- Operating income (annual): USD -24.81MSEC XBRL filing